Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Gross Margin: 2018-2025

Historic Gross Margin for Sunshine Biopharma (SBFM) over the last 7 years, with Sep 2025 value amounting to 32.64%.

  • Sunshine Biopharma's Gross Margin fell 134.00% to 32.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.01%, marking a year-over-year increase of 223.00%. This contributed to the annual value of 30.60% for FY2024, which is 402.00% down from last year.
  • As of Q3 2025, Sunshine Biopharma's Gross Margin stood at 32.64%, which was down 10.27% from 36.37% recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Gross Margin high stood at 64.98% for Q2 2021, and its period low was 25.33% during Q2 2024.
  • In the last 3 years, Sunshine Biopharma's Gross Margin had a median value of 33.41% in 2023 and averaged 32.89%.
  • Per our database at Business Quant, Sunshine Biopharma's Gross Margin crashed by 3,465bps in 2021 and then spiked by 1,105bps in 2025.
  • Sunshine Biopharma's Gross Margin (Quarterly) stood at 28.00% in 2021, then skyrocketed by 985bps to 37.85% in 2022, then crashed by 441bps to 33.44% in 2023, then crashed by 120bps to 32.24% in 2024, then slumped by 134bps to 32.64% in 2025.
  • Its last three reported values are 32.64% in Q3 2025, 36.37% for Q2 2025, and 30.67% during Q1 2025.